Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.

Di Nisio, M; Candeloro, M; Rutjes, A W S; Porreca, E (2018). Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. Journal of thrombosis and haemostasis, 16(7), pp. 1336-1346. Wiley-Blackwell 10.1111/jth.14149

[img]
Preview
Text
Nisio JThrombHaemost 2018.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (1MB) | Preview
[img] Text
DiNisio JThrombHaemostat 2018.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (292kB) | Request a copy

BACKGROUND Venous thromboembolism (VTE) is a frequent complication in cancer patients receiving adjuvant treatment. The risk of VTE during neoadjuvant chemo-radiotherapy remains unclear. OBJECTIVES This systematic review evaluated the incidence of VTE in patients with cancer receiving neoadjuvant treatment. METHODS MEDLINE and EMBASE databases were searched from inception to October 2017. Search results were supplemented with screening of conference proceedings of the American Society of Clinical Oncology (2009-2016) and the International Society of Thrombosis and Haemostasis (2003-2016). Two review authors independently screened titles and abstracts, and extracted data onto standardized forms. RESULTS Twenty-eight cohort studies (7827 cancer patients, range 11 to 1398) were included. Twenty-five had a retrospective design. Eighteen cohorts included patients with gastrointestinal cancer representing over two-thirds of the whole study population (n = 6002, 78%). In total, 508 of 7768 patients were diagnosed with at least one VTE during neoadjuvant treatment for a pooled VTE incidence of 7% (95% CI, 5% to 10%) in absence of substantial between study heterogeneity. Heterogeneity was not explained by site of cancer or study design characteristics. VTE presented as pulmonary embolism in 22% to 96% of cases (16 cohorts), and it was symptomatic in 22% to 100% of patients (11 cohorts). Highest VTE rates were observed in patients with bladder (10.6%) or esophageal (8.4%) cancer. CONCLUSIONS This review found a relatively high incidence of VTE in cancer patients receiving neoadjuvant therapy in the presence of some between study variation, which deserves further evaluation in prospective studies. This article is protected by copyright. All rights reserved.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)

UniBE Contributor:

Rutjes, Anne

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1538-7836

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Tanya Karrer

Date Deposited:

16 May 2018 15:21

Last Modified:

23 Oct 2019 18:58

Publisher DOI:

10.1111/jth.14149

PubMed ID:

29754426

Uncontrolled Keywords:

Neoadjuvant therapy meta-analysis neoplasms review venous thromboembolism

BORIS DOI:

10.7892/boris.116565

URI:

https://boris.unibe.ch/id/eprint/116565

Actions (login required)

Edit item Edit item
Provide Feedback